lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Inhibrx Biosciences, Inc.
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 21, 2026
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
April 20, 2026
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
March 19, 2026
Inhibrx Announces Participation in Upcoming Scientific Conference
March 2, 2026
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
December 23, 2025
Inhibrx Reports Third Quarter 2025 Financial Results
November 17, 2025
Inhibrx Announces Participation in Upcoming Scientific Conferences
November 7, 2025
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
October 24, 2025